Core Viewpoint - The company reported a strong performance in H1 2025, achieving revenue of 1.621 billion yuan, a year-on-year increase of 19.88%, and turning a profit with a net profit of 27 million yuan [1]. Revenue Performance - In H1 2025, the company achieved revenue of 1.621 billion yuan, reflecting a growth of approximately 20% year-on-year [2]. - The small molecule API business generated revenue of 1.500 billion yuan, also up 20% year-on-year [2]. - The gene and cell therapy business saw significant growth, with revenue increasing by 71% to 330 million yuan [2]. - The new molecule business experienced remarkable growth of 128%, generating revenue of 220 million yuan [2]. - The European market showed strong growth, with revenue of 509 million yuan, up 35% year-on-year, while North America generated 562 million yuan, a 33% increase [2]. Profitability and Margins - The overall gross margin for H1 2025 was approximately 28%, with a quarterly gross margin of about 29% in Q2 2025, indicating a sequential improvement [4]. - The small molecule API business achieved a gross margin of around 37%, showing signs of recovery [4]. - The net profit for H1 2025 was 27 million yuan, with Q2 2025 net profit reaching 31 million yuan, marking a turnaround to profitability [4]. - The net profit margin for the small molecule API business was calculated at 9.2%, with further adjustments indicating a recovery to over 10% [4]. New Business Opportunities - The new molecule business is expected to become a key driver of future performance, with new orders signed amounting to 41.86 million yuan in H1 2025 [3]. - The company has secured a comprehensive project for overseas dual-load ADC IND, serving 67 projects for 38 clients [3]. - The company’s facilities have passed European QP audits, laying the groundwork for global business expansion in the new molecule sector [3]. Investment Outlook - Revenue forecasts for 2025-2027 have been adjusted, with expected revenues of 3.526 billion, 4.141 billion, and 4.851 billion yuan respectively [5]. - Earnings per share (EPS) estimates have been revised to 0.16, 0.55, and 0.85 yuan for the same period [5]. - The company maintains a "buy" rating, anticipating a marginal improvement in performance over the medium to long term [5].

Investment Rating - The investment rating for the company is "Buy" [4] Core Views - The company's performance in H1 2025 met market expectations, with a significant recovery in its main business leading to profitability [2][3] - The small molecule API business continues to show rapid growth, contributing significantly to revenue [2][7] - The new molecular business is expected to become a new driver for the company's performance [7] Summary by Sections Event Overview - In H1 2025, the company achieved revenue of 1.621 billion yuan, a year-on-year increase of 19.88%, and a net profit attributable to shareholders of 27 million yuan, marking a return to profitability [1] Performance Analysis - The small molecule API business generated revenue of 1.5 billion yuan in H1 2025, up 20% year-on-year, while the gene and cell therapy business saw a 71% increase in revenue [2] - The overall gross margin for H1 2025 was approximately 28%, with a gross margin of about 29% in Q2 2025, indicating a recovery [3] Financial Forecast and Valuation - Revenue forecasts for 2025-2027 have been adjusted to 3.526 billion yuan, 4.141 billion yuan, and 4.851 billion yuan, respectively, with EPS estimates adjusted to 0.16 yuan, 0.55 yuan, and 0.85 yuan [7] - The company is expected to show a trend of marginal improvement in performance over the medium to long term [7]